Media Relations News Releases Year: - Any -201820172016 Items per page 102550 Aug 27, 2017 Summary ToggleNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk Aug 27, 2017 Summary ToggleNovartis announces exploratory analysis published in The Lancet showing ACZ885 reduced lung cancer mortality by 77% in the CANTOS study with further studies planned Aug 24, 2017 Summary ToggleNovartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Jul 25, 2017 Summary ToggleSandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries Jul 6, 2017 Summary ToggleNovartis receives approval in the EU for Cosentyx® label update, includes long term superiority data versus Stelara® in psoriasis Jun 23, 2017 Summary ToggleNovartis Kisqali® (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor Jun 15, 2017 Summary ToggleNovartis’ Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years Jun 8, 2017 Summary ToggleNovartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting May 4, 2017 Summary ToggleNovartis exercises exclusive option agreement with Conatus for the treatment of NASH Apr 28, 2017 Summary ToggleNovartis receives FDA approval for Rydapt® in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of systemic mastocytosis (SM) Pagination First page First Previous page Previous … Page 3 Current page 4 Page 5 Page 6 … Next page Next Last page Last
